Takeda Vaccines, Inc.

Takeda Vaccines (montana), Inc.

Ligocyte Pharmaceuticals, Inc.

Bryan Steadman

Charles Richardson

Thomas S Vedvick

Thomas R Foubert

Charles R Petrie

Joel R Haynes

Robert F Bargatze

Ross Taylor

Joel Haynes

Robert Bargatze

Methods for purifying human Calciviruses are disclosed, including Noroviruses and Sapoviruses.

Virus like particle purification

The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed.

Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity

The present invention provides particle-forming chimeric proteins comprising a Calicivirus capsid protein and one or more heterologous antigen sequences. In particular, the present invention discloses engineered Calicivirus capsid protein sequences containing heterologous epitopes fused at internal locations such that the modified capsid proteins retain the ability to form virus-like particles when expressed in host cells. Virus-like particles comprising the chimeric proteins and vaccine formulations are also described.

Targeted heterologous antigen presentation on calicivirus virus-like particles

Growing community of inventors

Bozeman, MT, United States of America

Bryan Steadman